Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

5.925 +0.295 (+5.24%)
Streaming Delayed Price Updated: 1:46 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Candel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at the SITC 2025 Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Participate in Upcoming Investor Conferences in September
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer
Interim CFO elevated to permanent role after demonstrating exceptional financial leadership, guiding the company through major operational and financial milestones 
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial development 
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at Upcoming Investor Conferences
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit when combining CAN-2409 and nivolumab with standard of care 
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment
From Candel Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.